Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II ZK219477 epothilone in recurrent glioblastoma
2005-005877-31Phase 2Completed
- Sponsor
- Carlo Besta Neurological Institute
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sagopilone in glioblastoma (GBM), sponsored by Carlo Besta Neurological Institute. Primary endpoints: Progression-free survival at 6 months and Treatment toxicity. Started Apr 2006; status: completed.
02
Drugs
sagopilone
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2005-005877-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005877-31.